RhumbLine Advisers’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

RhumbLine Advisers’s Portfolio KRSA Stock Details KRSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Hold	0	–	-$3	–	4269
2023 Q3	–	Sell	-3	Closed	-$11	–	4303
2023 Q2	$94	Buy	+3	New	+$16	﹤0.01%	4367
2021 Q2	–	Sell	-244	Closed	-$95K	–	3018
2021 Q1	$95K	Buy	244 +1	+0.4%	+$75	﹤0.01%	2940
2020 Q4	$104K	Buy	243 +33	+16%	+$2.25K	﹤0.01%	2965
2020 Q3	$179K	Sell	210 -34	-14%	-$3.89K	﹤0.01%	2720
2020 Q2	$202K	Buy	244 +56	+30%	+$4.68K	﹤0.01%	2767
2020 Q1	$70K	Hold	188	–	–	﹤0.01%	2834
2019 Q4	$72K	Buy	188 +2	+1%	+$187	﹤0.01%	2901
2019 Q3	$315K	Buy	186 +2	+1%	+$432	﹤0.01%	2555
2019 Q2	$295K	Buy	+184	New	+$52.1K	﹤0.01%	2614

Other funds holding KRSA

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return

TCP

Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RhumbLine Advisers's KRSA Position: Q4 2023 in Review

RhumbLine Advisers held its Korsana Biosciences, Inc. Common Stock (KRSA) position steady in Q4 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4269.

RhumbLine Advisers first reported a position in KRSA in Q2 2019 and has held it in 9 quarters since. The position peaked at $315K in Q3 2019. 14 funds tracked by Wall St. Rank hold KRSA as of Q4 2023.

RhumbLine Advisers held 0 shares of Korsana Biosciences, Inc. Common Stock worth $0 as of Q4 2023.
RhumbLine Advisers left its Korsana Biosciences, Inc. Common Stock share count unchanged in Q4 2023.
Korsana Biosciences, Inc. Common Stock made up ﹤0.01% of RhumbLine Advisers's portfolio in Q4 2023, its #4269 holding.
RhumbLine Advisers first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and has held it in 9 quarters since.
RhumbLine Advisers's Korsana Biosciences, Inc. Common Stock position peaked at $315K in Q3 2019.
14 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q4 2023.

Based on RhumbLine Advisers's 13F filing for Q4 2023, filed 8 Feb 2024.